Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: Letrozole/Abemaciclib +/- Metformin/Gedatolisib in ER+ Endometrial Cancer
NCT03675893Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2018
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib, letrozole, liquid metformin (Aspargo Labs), gedatolisib, samotolisib in endometrial cancer (EC), sponsored by Dana-Farber Cancer Institute. Started Dec 2018; status: recruiting.
02
Drugs
abemaciclibletrozoleliquid metformin (Aspargo Labs)gedatolisibsamotolisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03675893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675893.